Mylan PE Ratio 2006-2018 | MYL

Current and historical p/e ratio for Mylan (MYL) from 2006 to 2018. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Mylan PE ratio as of March 22, 2019 is 6.26.
Mylan PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2019-03-22 28.69 42.19
2018-12-31 27.40 $0.68 40.29
2018-09-30 36.60 $1.04 35.19
2018-06-30 36.14 $0.86 42.02
2018-03-31 41.17 $1.34 30.72
2017-12-31 42.31 $1.29 32.80
2017-09-30 31.37 $1.61 19.48
2017-06-30 38.82 $1.22 31.82
2017-03-31 38.99 $1.00 38.99
2016-12-31 38.15 $0.91 41.92
2016-09-30 38.12 $0.51 74.75
2016-06-30 43.24 $1.57 27.54
2016-03-31 46.35 $1.56 29.71
2015-12-31 54.07 $1.66 32.57
2015-09-30 40.27 $1.75 23.01
2015-06-30 67.86 $2.18 31.13
2015-03-31 59.35 $2.18 27.22
2014-12-31 56.37 $2.34 24.09
2014-09-30 45.49 $2.32 19.61
2014-06-30 51.56 $1.46 35.32
2014-03-31 48.83 $1.60 30.52
2013-12-31 43.40 $1.58 27.47
2013-09-30 38.17 $1.52 25.11
2013-06-30 31.03 $1.63 19.04
2013-03-31 28.96 $1.50 19.30
2012-12-31 27.45 $1.53 17.94
2012-09-30 24.37 $1.44 16.92
2012-06-30 21.37 $1.29 16.57
2012-03-31 23.45 $1.29 18.18
2011-12-31 21.46 $1.22 17.59
2011-09-30 16.99 $0.93 18.27
2011-06-30 24.67 $0.90 27.41
2011-03-31 22.66 $0.73 31.04
2010-12-31 21.13 $0.70 30.19
2010-09-30 18.81 $0.70 26.87
2010-06-30 17.04 $0.24 71.00
2010-03-31 22.71 $0.27 84.11
2009-12-31 18.43 $0.23 80.13
2009-09-30 16.01 $0.09 177.89
2009-06-30 13.05 $0.67 19.48
2009-03-31 13.41 $0.45 29.80
2008-12-31 9.89 $-1.17 0.00
2008-09-30 11.42 $-6.08 0.00
2008-06-30 12.07 $-5.93 0.00
2008-03-31 11.60 $-5.58 0.00
2007-12-31 14.06 $-4.43 0.00
2007-09-30 15.96 $1.24 12.87
2007-06-30 18.19 $1.00 18.19
2007-03-31 21.07 $1.03 20.46
2006-12-31 19.84 $1.34 14.81
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $14.803B $11.434B
Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as Mylan Inc., is based in Canonsburg, Pennsylvania.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $49.659B 8.94
Teva Pharmaceutical Industries (TEVA) Israel $16.606B 5.73
Bausch Health Cos (BHC) Canada $8.636B 6.14
Dr Reddy's Laboratories (RDY) India $6.502B 25.93
Supernus Pharmaceuticals (SUPN) United States $1.866B 17.31
Mallinckrodt Public Limited Company (MNK) United Kingdom $1.845B 3.00
Homology Medicines (FIXX) United States $0.967B 0.00
Amphastar Pharmaceuticals (AMPH) United States $0.943B 87.65
CymaBay Therapeutics (CBAY) United States $0.709B 0.00
Voyager Therapeutics (VYGR) United States $0.586B 0.00
Assembly Biosciences (ASMB) United States $0.465B 0.00
Akorn (AKRX) United States $0.440B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.366B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.210B 0.00
Sol-Gel Technologies (SLGL) Israel $0.127B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.122B 0.00
Acasti Pharma (ACST) Canada $0.082B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.064B 0.00
Agile Therapeutics (AGRX) United States $0.064B 0.00
Teligent (TLGT) United States $0.062B 0.00
Evoke Pharma (EVOK) United States $0.025B 0.00
China Pharma Holdings (CPHI) China $0.014B 0.00
Aevi Genomic Medicine (GNMX) United States $0.014B 0.00